Moreover, a dramatic response to combined Erlotinib and Crizotinib was reported in a patient with EGFRm+ NSCLC harboring a very high level of de novo MET amplification with an MET/CEN7 ratio >15 [89]. This evidence concerns the gene MET and non-small cell lung carcinoma.